ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more
ProKidney Corp. (PROK) - Total Liabilities
Latest total liabilities as of September 2025: $33.27 Million USD
Based on the latest financial reports, ProKidney Corp. (PROK) has total liabilities worth $33.27 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ProKidney Corp. - Total Liabilities Trend (2019–2024)
This chart illustrates how ProKidney Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ProKidney Corp. Competitors by Total Liabilities
The table below lists competitors of ProKidney Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nepes Corporation
KQ:033640
|
Korea | ₩458.11 Billion |
|
Zhuzhou Feilu High-Tech Materials Co Ltd
SHE:300665
|
China | CN¥1.17 Billion |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
USA | $68.49 Million |
|
SENCO GOLD LTD
NSE:SENCO
|
India | ₹37.73 Billion |
|
Medical Facilities Corporation
PINK:MFCSF
|
USA | $159.40 Million |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
India | ₹35.49 Billion |
|
Climb Bio Inc
NASDAQ:CLYM
|
USA | $7.27 Million |
|
Simulations Plus Inc
NASDAQ:SLP
|
USA | $10.72 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down ProKidney Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProKidney Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProKidney Corp. (2019–2024)
The table below shows the annual total liabilities of ProKidney Corp. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $39.44 Million | +34.98% |
| 2023-12-31 | $29.22 Million | +123.76% |
| 2022-12-31 | $13.06 Million | -2.42% |
| 2021-12-31 | $13.38 Million | +95.74% |
| 2020-12-31 | $6.84 Million | +83.57% |
| 2019-12-31 | $3.72 Million | -- |